Which has stronger valuation and earnings, ARTV or FLNA?

Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artiva Biotherapeutics N/A N/A -$83.86M -$3.54 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is ARTV or FLNA more profitable?

Cassava Sciences' return on equity of -53.90% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -73.15% -62.74% Cassava Sciences N/A -53.90% -34.20%

Does the media favor ARTV or FLNA?

In the previous week, Cassava Sciences had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 3 mentions for Cassava Sciences and 2 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.62 equaled Cassava Sciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, FLNA or AVXL?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$1.61 N/A Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A

Is FLNA or AVXL more profitable?

Anavex Life Sciences' return on equity of -38.76% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -53.90% -34.20% Anavex Life Sciences N/A -38.76% -35.01%

Does the media prefer FLNA or AVXL?

In the previous week, Cassava Sciences had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Cassava Sciences and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.08 beat Cassava Sciences' score of 0.62 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, NBP or FLNA?

I-Mab is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio I-Mab N/A N/A -$46.27M -$0.36 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is NBP or FLNA more profitable?

I-Mab's return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Cassava Sciences N/A -53.90% -34.20%

Does the media prefer NBP or FLNA?

In the previous week, I-Mab had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for I-Mab and 3 mentions for Cassava Sciences. I-Mab's average media sentiment score of 0.69 beat Cassava Sciences' score of 0.62 indicating that I-Mab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FLNA or DTIL?

In the previous week, Cassava Sciences had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Cassava Sciences and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.89 beat Cassava Sciences' score of 0.62 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, NERV or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is NERV or FLNA more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% Cassava Sciences N/A -53.90% -34.20%

Cassava Sciences (FLNA) Competitors

$0.89 -0.04 (-4.43%)

As of 07/24/2026 04:00 PM Eastern

Compare

FLNA vs. ARTV, AVXL, NBP, DTIL, and NERV

Should you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Artiva Biotherapeutics (ARTV), Anavex Life Sciences (AVXL), I-Mab (NBP), Precision BioSciences (DTIL), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical products" industry.

How does Cassava Sciences compare to Artiva Biotherapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Artiva Biotherapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, suggesting that its share price is 173% less volatile than the broader market.

Artiva Biotherapeutics currently has a consensus price target of $39.00, suggesting a potential upside of 288.83%. Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 461.23%. Given Cassava Sciences' higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	N/A	N/A	-$83.86M	-$3.54	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

38.0% of Cassava Sciences shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cassava Sciences' return on equity of -53.90% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-73.15%	-62.74%
Cassava Sciences	N/A	-53.90%	-34.20%

In the previous week, Cassava Sciences had 1 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 3 mentions for Cassava Sciences and 2 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 0.62 equaled Cassava Sciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cassava Sciences beats Artiva Biotherapeutics on 7 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Anavex Life Sciences?

Cassava Sciences (NASDAQ:FLNA) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Cassava Sciences has a beta of -0.73, indicating that its share price is 173% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Cassava Sciences presently has a consensus target price of $5.00, suggesting a potential upside of 461.23%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 788.89%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Cassava Sciences had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Cassava Sciences and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.08 beat Cassava Sciences' score of 0.62 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anavex Life Sciences' return on equity of -38.76% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Summary

Anavex Life Sciences beats Cassava Sciences on 9 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to I-Mab?

I-Mab (NASDAQ:NBP) and Cassava Sciences (NASDAQ:FLNA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, I-Mab had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 4 mentions for I-Mab and 3 mentions for Cassava Sciences. I-Mab's average media sentiment score of 0.69 beat Cassava Sciences' score of 0.62 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

I-Mab has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, indicating that its share price is 173% less volatile than the broader market.

I-Mab is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	N/A	N/A	-$46.27M	-$0.36	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

I-Mab's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Cassava Sciences	N/A	-53.90%	-34.20%

I-Mab currently has a consensus target price of $9.00, suggesting a potential upside of 408.47%. Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 461.23%. Given Cassava Sciences' higher probable upside, analysts plainly believe Cassava Sciences is more favorable than I-Mab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

38.4% of I-Mab shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 22.1% of I-Mab shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

I-Mab beats Cassava Sciences on 9 of the 11 factors compared between the two stocks.

How does Cassava Sciences compare to Precision BioSciences?

Cassava Sciences (NASDAQ:FLNA) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

38.0% of Cassava Sciences shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cassava Sciences currently has a consensus price target of $5.00, indicating a potential upside of 461.23%. Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 342.39%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Cassava Sciences had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 3 mentions for Cassava Sciences and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 1.89 beat Cassava Sciences' score of 0.62 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cassava Sciences has a beta of -0.73, meaning that its share price is 173% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market.

Precision BioSciences has higher revenue and earnings than Cassava Sciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A
Precision BioSciences	$45.07M	4.17	-$45.72M	-$3.67	N/A

Cassava Sciences has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Cassava Sciences' return on equity of -53.90% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-53.90%	-34.20%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Summary

Cassava Sciences beats Precision BioSciences on 9 of the 15 factors compared between the two stocks.

How does Cassava Sciences compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Minerva Neurosciences currently has a consensus target price of $10.50, suggesting a potential upside of 159.90%. Cassava Sciences has a consensus target price of $5.00, suggesting a potential upside of 461.23%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cassava Sciences had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for Cassava Sciences and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.87 beat Cassava Sciences' score of 0.62 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Very Positive
Cassava Sciences	Positive

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
Cassava Sciences	N/A	-53.90%	-34.20%

Minerva Neurosciences has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.73, meaning that its stock price is 173% less volatile than the broader market.

Summary

Cassava Sciences beats Minerva Neurosciences on 6 of the 11 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$43.04M	$3.08B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-0.55	20.29	27.11	23.64
Price / Sales	N/A	481.80	512.89	89.27
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	0.58	4.13	10.28	6.07
Net Income	-$90.97M	$65.94M	$3.60B	$331.99M
7 Day Performance	-15.95%	-4.16%	-1.27%	-0.63%
1 Month Performance	-23.20%	-3.76%	-0.37%	-2.00%
1 Year Performance	-62.09%	9.94%	18.30%	13.62%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	1.9679 of 5 stars	$0.89 -4.4%	$5.00 +461.2%	-64.6%	$43.04M	N/A	N/A	20
ARTV Artiva Biotherapeutics	3.7549 of 5 stars	$8.88 -7.9%	$39.00 +339.0%	+191.6%	$219.59M	$250K	N/A	81	Analyst Forecast Gap Up
AVXL Anavex Life Sciences	2.0808 of 5 stars	$2.36 -5.8%	$21.33 +805.9%	-81.2%	$218.24M	N/A	N/A	40	News Coverage Positive News
NBP I-Mab	2.4354 of 5 stars	$1.87 -1.8%	$9.00 +382.6%	N/A	$216.84M	N/A	N/A	380	News Coverage
DTIL Precision BioSciences	2.7126 of 5 stars	$8.37 -4.5%	$32.25 +285.5%	+45.8%	$215.95M	$34.26M	N/A	200	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. ARTV, AVXL, NBP, DTIL, and NERV

How does Cassava Sciences compare to Artiva Biotherapeutics?

Summary

How does Cassava Sciences compare to Anavex Life Sciences?

Summary

How does Cassava Sciences compare to I-Mab?

Summary

How does Cassava Sciences compare to Precision BioSciences?

Summary

How does Cassava Sciences compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. ARTV, AVXL, NBP, DTIL, and NERV

How does Cassava Sciences compare to Artiva Biotherapeutics?

Which has more volatility and risk, ARTV or FLNA?

Do analysts recommend ARTV or FLNA?

Which has stronger valuation and earnings, ARTV or FLNA?

Do institutionals and insiders hold more shares of ARTV or FLNA?

Is ARTV or FLNA more profitable?

Does the media favor ARTV or FLNA?

Summary

How does Cassava Sciences compare to Anavex Life Sciences?

Which has more volatility & risk, FLNA or AVXL?

Do analysts recommend FLNA or AVXL?

Do institutionals & insiders hold more shares of FLNA or AVXL?

Does the media prefer FLNA or AVXL?

Is FLNA or AVXL more profitable?

Which has better valuation and earnings, FLNA or AVXL?

Summary

How does Cassava Sciences compare to I-Mab?

Does the media prefer NBP or FLNA?

Which has more risk and volatility, NBP or FLNA?

Which has better valuation & earnings, NBP or FLNA?

Is NBP or FLNA more profitable?

Do analysts prefer NBP or FLNA?

Do institutionals and insiders hold more shares of NBP or FLNA?

Summary

How does Cassava Sciences compare to Precision BioSciences?

Do insiders & institutionals believe in FLNA or DTIL?

Do analysts recommend FLNA or DTIL?

Does the media favor FLNA or DTIL?

Which has more volatility and risk, FLNA or DTIL?

Which has higher valuation & earnings, FLNA or DTIL?

Is FLNA or DTIL more profitable?

Summary

How does Cassava Sciences compare to Minerva Neurosciences?

Which has stronger valuation and earnings, NERV or FLNA?

Do insiders & institutionals hold more shares of NERV or FLNA?

Do analysts recommend NERV or FLNA?

Does the media prefer NERV or FLNA?

Is NERV or FLNA more profitable?

Which has more risk and volatility, NERV or FLNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools